EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.663
https://www.valueinhealthjournal.com/article/S1098-3015(22)02867-4/fulltext
Title :
EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02867-4&doi=10.1016/j.jval.2022.09.663
First page :
Section Title :
Open access? :
No
Section Order :
10196